CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 17, 2020
Result type: Reports
Project Number: SR0652-000
Product Line: Common Drug Review

Generic Name: ozanimod

Brand Name: TBC

Manufacturer: Celgene Inc.

Indications: Multiple Sclerosis, relapsing - remitting

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS).

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open July 27, 2020
Call for patient input closed September 16, 2020

- Patient input submission received from MS Society of Canada

Submission received August 25, 2020
Submission accepted September 09, 2020
Review initiated September 14, 2020
Draft CADTH review report(s) provided to sponsor for comment November 30, 2020
Deadline for sponsors comments December 09, 2020
CADTH responses on draft review report(s) provided to sponsor January 08, 2021
Expert committee meeting (initial) January 20, 2021
Draft recommendation issued February 01, 2021
February 03, 2021